Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing–remitting multiple sclerosis
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Neurology"
DOI: 10.1007/s00415-019-09288-y
Abstract: Alemtuzumab, a monoclonal antibody against CD52, is a highly effective treatment of relapsing–remitting multiple sclerosis (RRMS), but it is known to cause secondary autoimmunity in 40% of patients [1]. We present a case of a… read more here.
Keywords: relapsing remitting; treatment; treatment relapsing; alemtuzumab ... See more keywords
Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
Sign Up to like & getrecommendations! Published in 2018 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2018.01.011
Abstract: Natalizumab (NTZ, Tysabri®; Biogen-Idec, Cambridge, MA, USA) is a humanized anti-α4 integrin monoclonal antibody, largely used in the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). Although the drug has shown great efficacy in clinical trials (AFFIRM… read more here.
Keywords: risk; relapsing remitting; treatment; treatment relapsing ... See more keywords
Ponesimod for the treatment of relapsing multiple sclerosis
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2020.1799977
Abstract: ABSTRACT Introduction Multiple Sclerosis (MS) is an immune-mediated, complex, chronic inflammatory, and neurodegenerative disease of the central nervous system. Among the several therapeutic options developed over the last decade for relapsing MS (RMS), fingolimod, a… read more here.
Keywords: multiple sclerosis; ponesimod; ponesimod treatment; treatment relapsing ... See more keywords
Cost-effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of comparative effectiveness research"
DOI: 10.2217/cer-2016-0056
Abstract: AIM To compare the cost-effectiveness of different disease-modifying therapies' strategies for treatment of relapsing-remitting multiple sclerosis. METHODS A Markov model was developed to assess the cost-effectiveness and incremental cost-effectiveness ratios for different strategies of using… read more here.
Keywords: relapsing remitting; cost; treatment relapsing; remitting multiple ... See more keywords
Treatment of relapsing multiple sclerosis – recommendations of the Croatian Neurological Society
Sign Up to like & getrecommendations! Published in 2022 at "Croatian Medical Journal"
DOI: 10.3325/cmj.2022.63.379
Abstract: Untreated multiple sclerosis (MS) irretrievably leads to severe neurological impairment. In European health care systems, patient access to disease modifying therapies (DMT) is often confined to more advanced stages of the disease because of restrictions… read more here.
Keywords: croatian neurological; neurological society; treatment relapsing; treatment ... See more keywords
Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Neurology"
DOI: 10.3389/fneur.2020.595547
Abstract: Several clinical trials have demonstrated the efficacy of lytic therapies targeting B cells in the treatment of relapsing multiple sclerosis (MS). More modest efficacy has been noted in the primary progressive subtype of MS. Clinical… read more here.
Keywords: treatment relapsing; multiple sclerosis; anti cd20; relapsing multiple ... See more keywords